High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition.

MLA

James, Daniel, et al. “High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition.” Case Reports in Hematology, vol. 2024, Nov. 2024, pp. 1–4. EBSCOhost, https://doi.org/10.1155/2024/1813512.

APA

James, D., Green, S., Molica, S., Allsup, D., & Piccaluga, P. P. (2024). High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition. Case Reports in Hematology, 2024, 1–4. https://doi.org/10.1155/2024/1813512

Chicago

James, Daniel, Simone Green, Stefano Molica, David Allsup, and Pier Paolo Piccaluga. 2024. “High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition.” Case Reports in Hematology 2024 (November): 1–4. doi:10.1155/2024/1813512.